Last reviewed · How we verify
Keytruda — patents & exclusivity
Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response.
Patents
| Number | Expiry | Type | Status |
|---|---|---|---|
| Composition of matter | Active | ||
| Composition of matter | Active | ||
| Composition of matter (EU) | Active | ||
| Composition of matter (JP) | Active | ||
| Method of treatment | Active | ||
| Subcutaneous formulation | Active | ||
| BPCIA reference-product exclusivity | Active |
See also
- Full profile: Keytruda
- Side effects: /side-effects
- Dosage & administration: /dosage
- Mechanism of action: /mechanism
- Cost & pricing: /cost
- Drug interactions: /interactions
- Clinical trials: /clinical-trials
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing